<DOC>
	<DOCNO>NCT00699192</DOCNO>
	<brief_summary>To characterize safety , tolerability , efficacy profile amlodipine/valsartan 5/80 mg compare amlodipine/valsartan 5/40 mg ( optional titration 5/80 mg ) amlodipine 5 mg monotherapy elderly patient ( ≥ 65 year age ) essential hypertension . All three regimen expect well tolerate .</brief_summary>
	<brief_title>Safety , Tolerability , Efficacy Once Daily Amlodipine/Valsartan 5/80 Compared Amlodipine/Valsartan 5/40 Amlodipine 5 mg Monotherapy Patients 65 Years Age Older With Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Amlodipine , Valsartan Drug Combination</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Inclusion criterion Provide write informed consent assessment perform . Male female least 65 year age . Diagnosed hypertension : At Visit 1/Screening , treatment naïve patient mean seat SBP ≥ 155 mmHg &lt; 180 mmHg ; patient undergo washout previous antihypertension medication mean seat SBP &lt; 180 mmHg . At Visit 2/Singleblind runin entry , patient mean seat SBP ≥ 155 mmHg &lt; 180 mmHg . At Visit 3/Core doubleblind treatment period entry , patient mean seat SBP ≥ 145 mmHg &lt; 180 mmHg . Ability communicate comply study requirement include measure blood pressure home , daily instruct , use home blood pressure monitor provide Sponsor . Female patient postmenopausal least one year . Exclusion criterion Severe hypertension ( mean seat SBP ≥ 180 mmHg and/or mean seat DBP ≥ 110 mmHg ) . History secondary hypertension ( include primary aldosteronism , renovascular hypertension , pheochromocytoma , etc. ) . Use three antihypertensive drug . Dual fix dose combination therapy consider two antihypertensive drug . Administration agent indicate treatment hypertension Visit 1 , permit exception antihypertensive medication require tapering ( e.g . betablocker and/or clonidine ) commence Visit 1 . Known moderate malignant retinopathy . Moderate define retinal sign hemorrhage , microaneurysm , cottonwool spot , hard exudate , combination thereof ; malignant define sign moderate retinopathy plus swelling optic disk . Known suspected contraindication , include history allergy hypersensitivity angiotensin receptor blocker ( ARB ) , calcium channel blocker ( CCB ) , drug similar chemical structure . History cerebrovascular accident , thrombotic stroke , transient ischemic attack . Significant history coronary artery disease ( CAD ) history myocardial infarction ( MI ) , angina pectoris , type revascularization procedure . History diagnosis congestive heart failure Grade IIIV accord New York Heart Association ( NYHA ) classification . Clinically significant valvular heart disease . All patient Type 1 diabetes mellitus patient Type 2 diabetes mellitus , opinion investigator , well control . Patients need oral antidiabetic medication adequately control Type 2 diabetes stable dose oral antidiabetic medication least 4 week prior Visit 1 . Concomitant potentially life threaten arrhythmia symptomatic arrhythmia . Second third degree heart block without pacemaker . Significant hepatic disease , demonstrate one following : aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) value great two time upper limit normal Visit 1 , history hepatic encephalopathy , history esophageal varix , history portocaval shunt . Evidence renal impairment determine one following : glomerular filtration rate ( GFR ) &lt; 50 ml/min/1.73m2 measure Modification Diet Renal Disease ( MDRD ) formula Visit 1 , history dialysis , history nephrotic syndrome . History clinically significant allergy include asthma and/or multiple drug allergy . Any surgical medical condition potential significantly alter absorption , distribution , metabolism , excretion drug include limited following : history major gastrointestinal tract surgery gastrectomy , gastroenterostomy , bowel resection , gastric bypass , gastric stapling , gastric banding , currently active inactive inflammatory bowel syndrome within 12 month prior Visit 1 , currently active gastritis , ulcer , gastrointestinal/rectal bleeding , urinary tract obstruction regard clinically meaningful investigator . Any condition , identify protocol , , opinion investigator Novartis monitor , place patient high risk his/her participation study , likely prevent patient comply requirement study complete trial period . History malignancy organ system , treat untreated , within past 5 year whether evidence local recurrence metastasis , exception localize basal cell carcinoma skin . Any chronic inflammatory condition need chronic antiinflammatory therapy . History drug alcohol abuse within last 2 year . Use investigational drug time enrollment , within 30 day prior Visit 1 ( Week 8 ) . Inability communicate comply study requirement include unwillingness inability provide inform consent . Persons directly involved execution protocol . History noncompliance medical regimen , patient unwilling comply study protocol . Any severe , lifethreatening disease within past five year .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Blood pressure</keyword>
	<keyword>hypertension</keyword>
	<keyword>elderly</keyword>
</DOC>